Amylyx Pharma Names Patrick Yeramian Chief Medical Officer

Amylyx Pharmaceuticals has appointed Patrick Yeramian to serve as its chief medical officer. Yeramian had been a consulting medical director for Cambridge, MA-based Amylyx. His experience also includes the chief medical officer post at Viragen. In other moves, Amylyx named Margaret Olinger chief commercial officer. Olinger joins Amylyx from Alexion Pharmaceuticals (NASDAQ: [[ticker:ALXN]]), where she was vice president, head of global Strensiq therapeutic area. Amylyx is developing treatments for amyotrophic lateral sclerosis, Alzheimer’s disease, and other neurodegenerative disorders.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.